Cargando…
Systematically understanding the immunity leading to CRPC progression
Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in American men. Androgen deprivation therapy (ADT) has become a standard treatment strategy for advanced PCa. Although a majority of patients initially respond to ADT well, most of t...
Autores principales: | Ji, Zhiwei, Zhao, Weiling, Lin, Hui-Kuan, Zhou, Xiaobo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754164/ https://www.ncbi.nlm.nih.gov/pubmed/31504033 http://dx.doi.org/10.1371/journal.pcbi.1007344 |
Ejemplares similares
-
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019) -
Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer
por: Kang, Ning, et al.
Publicado: (2023) -
Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022) -
Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
por: Li, Yan, et al.
Publicado: (2022) -
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)